retatrutide study results New Phase 3 data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats 🚨 Today, retatrutide, the GIP/GLP-1/glucagon

Research indicates potential mechanisms including: Increased dopamine release in the mPOA following MC4R activation Enhanced dopaminergic neuron activity in reward pathways Modulation of dopamine receptor sensitivity in sexual behavior circuits Indirect effects on mesolimbic reward processing Animal studies using microdialysis demonstrated elevated extracellular dopamine levels in the mPOA following PT-141 administration, suggesting dopamine release may mediate some behavioral effects

The 25 comes from the GHK-Cu, not the vials total mass

Fatty acid composition and phospholipid types used in infant formulas modifies the establishment of human gut bacteria in germ-free mice

Particularly bad stuff

Girish 2009)